Head-To-Head Review: Gilla (GLLA) versus H. Lundbeck A/S- (HLUYY) - Fairfield Current

Gilla (OTCMKTS:GLLA) and H. Lundbeck A/S- (OTCMKTS:HLUYY) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Volatility and Risk

Gilla has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500. Comparatively, H. Lundbeck A/S- has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Valuation & Earnings

This table compares Gilla and H. Lundbeck A/S-‘s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gilla $4.60 million 1.19 -$6.64 million N/A N/A
H. Lundbeck A/S- $2.62 billion 3.33 $398.58 million $2.51 17.46

H. Lundbeck A/S- has higher revenue and earnings than Gilla.

Profitability

This table compares Gilla and H. Lundbeck A/S-‘s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gilla -137.19% N/A -130.57%
H. Lundbeck A/S- 20.26% 36.99% 21.75%

Analyst Recommendations

This is a summary of current ratings for Gilla and H. Lundbeck A/S-, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilla 0 0 0 0 N/A
H. Lundbeck A/S- 2 1 1 0 1.75

Institutional & Insider Ownership

0.1% of H. Lundbeck A/S- shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

H. Lundbeck A/S- pays an annual dividend of $0.95 per share and has a dividend yield of 2.2%. Gilla does not pay a dividend. H. Lundbeck A/S- pays out 37.8% of its earnings in the form of a dividend.

Summary

H. Lundbeck A/S- beats Gilla on 9 of the 11 factors compared between the two stocks.

Gilla Company Profile

Gilla Inc. engages in the manufacture, marketing, and distribution of generic and premium branded e-liquid used in vaporizers, electronic cigarettes, and other vaping hardware and accessories in Europe, Canada, and the United States. The company offers its products under the brand names of Spectrum Concentrates, Coil Glaze, Craft Vapes, Siren, The Drip Factory, Shake It, Surf Sauce, Ohana, Moshi, Crisp, Just Fruit, Vinto Vape, Vapor's Dozen, Enriched Vapor, and Crown E-liquid. Gilla Inc. sells its products through market channels, including vape shops, retail and wholesale distributors, convenience stores, and e-commerce Websites. The company is headquartered in Daytona Beach, Florida.

H. Lundbeck A/S- Company Profile

H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine. The company offers pharmaceutical products for the treatment of Alzheimer's disease, depression, Parkinson's disease, Schizophrenia, alcohol dependence, anxiety, Bipolar I disorder, Epilepsy, Huntington's disease, and symptomatic neurogenic orthostatic hypotension. H. Lundbeck A/S sells its products to distributors of pharmaceuticals, pharmacies, and hospitals. The company was founded in 1915 and is headquartered in Valby, Denmark.

Receive News & Ratings for Gilla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilla and related companies with MarketBeat.com's FREE daily email newsletter.



http://bit.ly/2R6j2DC
-

Comments

Post a Comment

Popular Posts

High blood pressure warning - the age you should definitely get checked for hypertension - Express

Image
High blood pressure is a common condition that puts extra stress on blood vessels and vital organs. Diagnosing the condition - which is also known as hypertension - early is crucial, as it raises the risk of some deadly complications, including heart disease and strokes. But making some small diet or lifestyle changes could help to lower your chances of developing high blood pressure . You should definitely get a blood pressure check as soon as you turn 60 years old, urged LloydsPharmacy. Hypertension is most common in people over 60 years old, said LloydsPharmacy. As soon as you’ve hit 60, it’s a good idea to speak to a doctor our pharmacist to check your blood pressure. Even if you only have slightly high blood pressure, diagnosing the condition early can help patients to kickstart their new lifestyle changes, it said. “It’s only natural that people might not think to seek help from a health professional until something starts to feel wrong, especially as we are all livin...
Read more

Real Stories From People Who Had a Surprising Gut Feeling That Turned Out to Be Correct - Obsev

Some people claim to have a sixth sense that lets them know when something is about to happen. Although most people aren't clairvoyant, there is some truth to having a gut feeling about future events. People have claimed to turn down job offers, decline evening plans and forgo vacations just because they had a feeling that things were about to take a turn for the worse. And when these feelings prove to be right, it's evident that maybe there is a reason that people have these instincts. The gut wrenching feeling that you have to act now just can't be ignored. Having a life-threatening experience is memorable enough, but narrowly avoiding one by seconds is just as unforgettable.   He's Still in Jail Unsplash My oldest daughter (30-something) stopped by my work one day and introduced her new boyfriend. He seemed a little off to me, but I decided it was just "guy dating my daughter" and let it go. La...
Read more

Atherosclerosis common in adults without heart disease, symptoms

Image
clinical trials day :: Article Creator Everyday Drug Discovery: How Tech Expands The Potential Of Clinical Trials And Recentres Participants Throughout my career in the development and implementation of technological solutions to support clinical research, I've been lucky enough to work closely with a wide range of so-called "stakeholders" in the clinical trial lifecycle, from regulators, drug development research teams, site staff, and patients.  While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients' willingness to sacrifice their time and adapt their care plans to take part in clinical trials, fully understanding they might not directly benefit from the treatment being tested, though so often desperately hoping they do. Patients recognise the importance of clinical research to the long term success in treating diseases of all kinds, and in turn the industry has t...
Read more